Review of NICE Technology Appraisal Guidance No 117; cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy - proposal to defer the review

As you may be aware the planned date for review of the above guidance was December 2009.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

The Institute has carried out a search for information relevant to this appraisal, and has found that to the best of its knowledge, no new evidence has been published that would have a material effect on the original guidance.  However, we are aware of a relevant on-going EVOLVE trial. Consequently we propose that the review of the original guidance be deferred until results of this trial are available.  At this point the evidence base will again be assessed to ascertain the need for a review of the current guidance.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial.  Please see appendix A for a full list of the organisations we have contacted.

Please note all comments received will be published on the Institute’s website when a decision has been taken. 

February 2010